Reported malignancies of unrelated PBSC donors facilitated by the NMDP, 1999-2004
New malignancy reported in donor . | n . | Time to onset after collection, mo . |
---|---|---|
Breast cancer | 5 | 4, 17, 40, 46, 72-84 |
Prostate cancer | 4 | 17, 26, 33, 60 |
Basal cell carcinoma | 4 | 5, 48, 52, 48-60 |
Melanoma | 3 | 33, 40, 72 |
Melanoma in situ | 2 | 16, 26 |
Laryngeal squamous cell carcinoma | 1 | 1 |
Renal cell adenocarcinoma | 1 | 6 |
Testicular embryonic carcinoma | 1 | 13 |
Lung cancer | 1 | 27 |
Esophageal cancer | 1 | 33 |
Uterine cancer | 1 | 47 |
Chronic lymphocytic leukemia | 1 | 60 |
Cervical cancer | 1 | 94 |
New malignancy reported in donor . | n . | Time to onset after collection, mo . |
---|---|---|
Breast cancer | 5 | 4, 17, 40, 46, 72-84 |
Prostate cancer | 4 | 17, 26, 33, 60 |
Basal cell carcinoma | 4 | 5, 48, 52, 48-60 |
Melanoma | 3 | 33, 40, 72 |
Melanoma in situ | 2 | 16, 26 |
Laryngeal squamous cell carcinoma | 1 | 1 |
Renal cell adenocarcinoma | 1 | 6 |
Testicular embryonic carcinoma | 1 | 13 |
Lung cancer | 1 | 27 |
Esophageal cancer | 1 | 33 |
Uterine cancer | 1 | 47 |
Chronic lymphocytic leukemia | 1 | 60 |
Cervical cancer | 1 | 94 |
Median follow-up, 49 months; range, 2 days to 99 months.
PBSC indicates periopheral blood stem cell; and NMDP, National Marrow Donor Program.